Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trialNicole Basset‐Séguin, Johan Hansson, Reinhard Dummer et al.|European Journal of Cancer|2017Cited by 284
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trialNicole Basset‐Séguin, Johan Hansson, Axel Hauschild et al.|The Lancet Oncology|2015Cited by 244
Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE studyJohan Hansson, Axel Hauschild, Karen Bartley et al.|European Journal of Dermatology|2018Cited by 26
Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study.Reinhard Dummer, Axel Hauschild, Nicole Basset‐Séguin et al.|Journal of Clinical Oncology|2015Cited by 22
Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts).Johan Hansson, Nicole Basset‐Séguin, Axel Hauschild et al.|Journal of Clinical Oncology|2016Cited by 7